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Use of FCC-NMRD relaxometry 
for early detection and 
characterization of ex-vivo murine 
breast cancer
enza Di Gregorio1, Giuseppe Ferrauto1, stefania Lanzardo1, eliana Gianolio1 & silvio Aime1,2
Breast Cancer is the most diffuse cancer among women and the treatment outcome is largely 
determined by its early detection. MRI at fixed magnetic field is already widely used for cancer 
detection. Herein it is shown that the acquisition of proton T1 at different magnetic fields adds further 
advantages. In fact, Fast Field Cycling Nuclear Magnetic Resonance Dispersion (FFC-NMRD) profiles 
have been shown to act as a high –sensitivity tool for cancer detection and staging in ex vivo murine 
breast tissues collected from Balb/NeuT mice. From NMRD profiles it was possible to extract two new 
cancer biomarkers, namely: (i) the appearance of 14N-quadrupolar peaks (QPs) reporting on tumor onset 
and (ii) the slope of the NMRD profile reporting on the progression of the tumor. By this approach it 
was possible to detect the presence of tumor in transgenic NeuT mice at a very early stage (5–7 weeks), 
when the disease is not yet detectable by using conventional high field (7 T) MRI and only minimal 
abnormalities are present in histological assays. These results show that, NMRD profiles may represent 
a useful tool for early breast cancer detection and for getting more insight into an accurate tumor 
phenotyping, highlighting changes in composition of the mammary gland tissue (lipids/proteins/water) 
occurring during the development of the neoplasia.
Breast Cancer is a multifactorial disease, considered a major public-health issue worldwide and the second cause 
of cancer-associated death among women1,2. The majority of breast cancers develops over extended periods of 
time arising from early, pre-invasive lesions such as atypical ductal hyperplasia (ADH) and ductal carcinoma in 
situ (DCIS), progressing to invasive carcinoma (IC) and culminating in the metastatic disease3. Early diagnosis 
is considered crucial for the success of the applied breast cancer therapy4. Recent years have witnessed a great 
progress in early diagnosis of breast cancer and in the design of personalized treatments, specific for the various 
tumor phenotypes.
Several imaging techniques are available for diagnosis, namely mammography, magnetic resonance imag-
ing (MRI), positron-emission tomography (PET), single-photon emission computed tomography (SPECT), 
Computed tomography (CT) and Ultrasounds (US)5–9.
Currently, mammography and/or US10,11 are the gold standard techniques used for population screening. 
More informative images can be obtained by using Magnetic Resonance Imaging (MRI), which provides detailed 
images of deep tissues, with a very high spatio-temporal resolution, without using ionizing radiation and with a 
limited invasiveness5,12,13.
Often, MR images are obtained without the administration of exogenous contrast agents, simply by exploiting 
the endogenous contrast generated by the differences in transverse and longitudinal water proton relaxation times 
(T2 and T1) between healthy and tumor tissues14–16.
We surmise that further, relevant information may be obtained by exploiting the T1 dependence of protons 
tissue from the applied magnetic field strength (B0). This task cannot be yet accomplished on the available MRI 
scanners, because they work at fixed B0. Nevertheless, the acquisition of the so called Fast Field Cycling–Nuclear 
Magnetic Dispersion (FFC-NMRD) profiles17–19 on ex vivo tissues can provide useful insights into the potential 
diagnostic value of Field-dependent T1-based approach20.
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These profiles report about 1H water relaxation rate, R1 (where R1 = 1/T1), over an extended range of magnetic 
fields. Their analysis can provide useful information about tissue water dynamics and the presence of lipids, pro-
tein and paramagnetic species as well as the interaction of water with proteins and other macromolecules14–16,19–21.
In this study, BALB-neuT transgenic mice have been used as breast cancer models22. Transgenic mouse mod-
els of breast cancer provide evident advantages in preclinical studies compared to xenografted ones. In fact, the 
latter model appears more suitable to represent advanced stages of cancer, whereas transgenic mice recapitulate 
the stepwise progression and typical features of several human cancers, maintaining the characteristic interac-
tions that naturally occur between tumors and their surrounding microenvironment22. BALB-neuT mice show a 
human-like breast cancer development, passing from mammary hyperplasia to atypical hyperplasia, and in situ 
carcinoma (CIS) and finally, to invasive breast cancer3,22. Breast tissue specimens from mice at different tumor 
stages of development have been analyzed by acquiring FFC-NMRD (Fast Field Cycling- Nuclear Magnetic 
Resonance Dispersion) profiles, without the administration of exogenous contrast agents (CAs). Correlations 
between the NMRD read-out and tumor stages/phenotypes have been assessed.
Methods
Animals. Female BALB/c mice (12-weeks) were purchased from Charles River Laboratories (Calco, Italy) and 
used as healthy control. BALB-neuT mice22 (5–30 weeks) were bred at the Molecular Biotechnology Center of the 
University of Torino (It).
Experiments involving animal testing were carried out at the Molecular Biotechnology Center at the University 
of Torino (Italy). Mice were kept in standard housing (12 h light/dark cycle) with rodent chow and water available 
ad libitum). Experiments were performed according to the Amsterdam Protocol on Animal Protection and in 
conformity with institutional guidelines that are in compliance with national laws (D.L.vo 116/92, D.L.vo 26/2014 
and following additions) and international laws and policies (EEC Council Directive 86/609, OJL 358, Dec 1987; 
NIH Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996).
This study was carried out in the framework of a protocol approved by Italian Ministry of Health 
(n807/2017-PR 19/10/2017).
MRI acquisition. For the MRI experiments, mice were anesthetized by intramuscular injection of a mixture 
of Tiletamine/Zolazepam (Zoletil 100, Virbac, Milan, Italy) 20 mg/kg and xylazine (Rompun; Bayer, Milan, Italy) 
5 mg/kg.
MR images were acquired at 7.1 T on a Bruker Avance 300 spectrometer equipped with the Micro 2.5 micro-
imaging probe at room temperature (R.T. = 21 °C).
High resolution T2W images were acquired by using a RARE (Rapid Acquisition with Refocused Echoes) 
sequence with the following parameters: Repetition time (TR) = 4000 ms, Echo time (TE) = 36 ms, RARE fac-
tor = 8, flip angle (FA) = 180°, number of averages(NA) = 8, Field of view (FOV) = 40 mm × 40 mm, slice thick-
ness = 0.5 mm, matrix size 384 × 384, spatial resolution = 0.104 mm/pixel × 0.104 mm/pixel).
FFC-NMRD profiles acquisition and data analysis. Mice were sacrificed by cervical dislocation, in 
agreement with ethical European guidelines. All mammary glands were gently scraped from the skin and divided 
into two parts, respectively used for i) the acquisition of FFC-NMRD (Fast Field Cycling- Nuclear Magnetic 
Resonance Dispersion) profiles and ii) for the histological analysis.
Mammary glands at different tumor stage (5–7w, 15w, 21w, 30w) and mammary glands from healthy control 
mice (N > 8) were analyzed and data were reported as mean ± SD. Tissue were placed into 10-mm NMR tubes 
without the addition of any medium or buffer, in order to avoid the addition of water to the specimen.
Nuclear magnetic resonance dispersion profile (NMRD) were acquired at 25 °C over a continuum of mag-
netic field strength from 0.01 to 21.5 MHz proton Larmor frequencies (corresponding to B0 = 0.24 mT-0.5 T) on 
the Stelar SpinMaster FFC NMR relaxometer (Stelar S.n.c., Mede (PV), Italy). The signal is placed on resonance 
and tuned at the proton Larmor frequency of each analyzed magnetic field. The applied sequences were the Pre 
Polarized sequence (PP/S) between 0.01 MHz and 7 MHz and the Non-Polarized sequence (NP/S) between 7 and 
21.5 MHz, respectively. Sixteen delay times (τ) between pulses were used. T1 was determined by applying the sat-
uration recovery function and analyzed as a mono-exponential decay (Bloch equation). The reported longitudinal 
relaxation rate (R1) corresponds to 1/T123. The total acquisition time is less than 50 minutes.
Analytical analysis of QPs (Quadrupolar peaks) was carried out according to mathematical models and pro-
cedures reported in literature by using Origin 9 software24–26.
The region containing the quadrupolar peaks was highlighted by subtracting the background of the R1 disper-
sion curve. The procedure relied on the fitting of the background using a bi-exponential model, which was found 
empirically to fit closely to the background data (i.e. experimental data in the regions not covering peaks’ region, 
B0 < 9 mT and B0 > 90 mT). The background contribution was then subtracted to the experimental NMRD pro-
files to make more visible the occurrence of QPs.
Histological analysis. Specimens for histology were fixed in 10% Neutral Buffered Formalin (Bio-Optica, 
Milan, Italy) and then embedded in paraffin; 5 μm slides were cut and placed in glass slides for histology. Sections 
were deparaffinized in xylol, rehydrated in graded alcohol series (Sigma Aldrich, Milano, Italy), then washed in 
water and stained with Hematoxylin (BioOptica) and Eosin (BioOptica) (H&E) for histological examination. The 
slices were analyzed on an Olympus 41microscope.
statistical analysis. Data are represented as mean ± SD. A paired two-tail Student’s t-test was used for all 
the experiments.
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In vitro validation studies. The mixture of tissues (adipose and epithelial) present in mammary gland in 
the presence of tumor has been simulated in vitro by mixing cross-linked albumin (representative of epithelial 
tissue) and oil (representative of fat tissue).
Cross-linked albumin was obtained by using a well-established procedure27,28. Briefly, BSA (Bovine Serum 
Albumin, Sigma Aldrich) was dissolved in water (150 mg/mL) and the solution placed in a heated bath at 80 °C 
for 10 minutes. The heating led to the formation of a semisolid system containing immobilized cross-linked pro-
teins. Then, the cross-linked BSA has been gently mixed with oil at different ratios (i.e. BSA/oil is 0, 0.1, 0.33, 0.50, 
0.66, 1).
NMRD profiles have been acquired and analyzed as done for animal tissues.
Results
Balb-NeuT mice have been investigated at different stage of their growth, i.e.at the age of (i) 5–7w, (ii) 15w, (iii) 
21w and (iv) 30w, respectively. As control, healthy female Balb/c mice have been used. All mice underwent MRI 
scans to monitor the tumor growth.
In Fig. 1 representative T2w MR Images (axial slices) of mice at the four considered stages are reported and 
compared with control mice. In the first stage of development (5–7 week), tumor is not detectable by MRI. Breast 
displays the same morphology and MR contrast cannot differentiate diseased from healthy mice. At the age of 15 
weeks, the presence of cancer cells embedded in the fatty matrix of the mammary gland tissue is barely detectable 
by MRI. Tumor becomes well visible in the MR images taken at 21–30 weeks, when the entire breast region is 
invaded by cancer cells. Therefore, the detection threshold by a typical MRI-T2 scan may be set at 15 weeks. At 
each time point, after the acquisition of MR images, mammary glands were excised and their NMRD profiles 
recorded.
The R1( = 1/T1) data acquired on the FFC spectrometer have been plotted against the applied magnetic field 
strength which varied, as expressed in terms of Larmor Frequencies, in the 0.01–10 MHz range (Fig. 2A,B).
At low fields (i.e B0 < 2.4 mT, corresponding to 0.1 MHz) R1 increases in the presence of cancer, especially at 
the advanced stage (Fig. 2A). On the contrary, at higher magnetic fields (i.e. > 2.4 mT, corresponding to 0.1 MHz) 
R1 decreases in presence of cancer (Fig. 2B). Overall this finding appears consistent to our current understanding 
of T1 values of tumor tissue at the imaging fields. It is a common understanding that T1 of tumor tissue are slightly 
longer (ca.10%) than the corresponding values in healthy ones. However, the herein reported data (Fig. 2) call for 
a peculiar behavior as the T1 difference between healthy and tumor tissue appears much larger.
Likely, the observed behavior is associated to the chemical composition of mammary gland cells that are 
largely represented by adipocytes, i.e by cellular systems in which the protein/fat/water ratio is profoundly altered 
in respect, for instance, to muscle, epithelium or brain cells. Interestingly, as shown in Fig. 2B (magnification of 
Fig. 2A), characteristics 14N-quadrupolar peaks (14N-QPs) can be detected, due to the 14N-1H cross-relaxation 
phenomena occurring between water protons and N-H moieties of semi-solid proteins24–26. These peaks (at 0.7, 
2.1 and 2.8 MHz) are absent in the NMRD profiles of the mammary gland tissue of healthy Balb/c mice but they 
are invariantly present in the NMRD profiles of NeuT mice at all stages of tumor development, already from the 
first investigated time point (5–7w). The subtraction of the tissue’s background component allows to detect the 
Figure 1. Axial T2w MR Images of Balb/C-NeuT mice at different growth stages and health Balb/c control 
(white arrows indicates breast/tumor regions).
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occurrence of 14N-QPs at all tumor development (starting at the 5–7w stage). Figure 2C reports the QPs region for 
representative tissues at 5–7w, 15w and 21–30w.
Overall, the NMRD profiles display a monoexponential decay when the data are represented in a semiloga-
ritmic graph. Therefore, by translating them in a log/log graph, it has been possible to fit the obtained data with 
a linear function (Fig. 2D). The slope of straight line connecting R1 data for healthy mice is very small (ca. 0.1). 
The slope is maintained small in the presence of tumors at very early stages (5–7 weeks). As the tumors grow, this 
value increases by reaching the values of 0.12, 0.19, 0.32 and 0.34 at 7w, 15w, 21w and 30w, respectively (Fig. 2E). 
The small slope value observed for healthy mice appears typical of the presence of a tissue whose main compo-
nent is still represented by lipids. On the contrary, large slope values (e.g. NeuT at 21w and 30w) are typical of the 
presence of epithelial tissue, as present in breast cancers at later development stages. The transition zone (NeuT at 
7w and 15w) are composed by samples with a mixture of fat and epithelial tissues.
14N-QPs are not present in healthy breast tissue while they are evident in mice from 5–7w (Fig. 2A,B). 
Inspection into the NMRD profiles showed that QPs’ amplitude are relatively similar at the different tumor stages. 
Thus the appearance of the QPs in the NMRD profiles appears as a unique tumor biomarker. It is remarkable that 
14N-QPs are already present in specimens at a very early stage of tumor development (5–7w).
NMRD data were correlated to histological analysis. NeuT mammary glands are characterized by a mosaic of 
different histological phenotypes (simple hyperplasia, atypical hyperplasia, carcinoma in situ, invasive cancer), 
whose relative abundance depends on the tumor stage (Fig. 3)29,30.
Figure 2. (A) NMRD profiles of breast cancer at different stages (7, 15, 21 and 30 weeks) and of control healthy 
breast tissue (Mean ± SD of at least 8 independent specimens). (B) Magnification of the NMRD profiles in 
the region 0.1–10 MHz range; (C) Representative QPs obtained by subtracting background (5–7w, 15w and 
21–30w), (D) Linear fitting of NMRD profiles (in the log/log scale) and (E) slope of the linear fitting for control 
and NeuT mice at different stage of tumor growth (Mean ± SD) (*P-value < 0.1).
5Scientific RepoRts |          (2019) 9:4624  | https://doi.org/10.1038/s41598-019-41154-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
In 5–7w mice, they are mainly composed by adipose tissue, with some foci of simple hyperplasia (Fig. 3B). In 
15w mice, simple hyperplasia plus atypical hyperplasia represents the larger part of the gland (Fig. 3C). At 21w, 
most of the gland is composed by simple and atypical hyperplasia with the occurrence of large foci of carcinoma 
in situ (CIS) (Fig. 3D). Finally, in 30w mice, more than half of the gland is composed by CIS and invasive carci-
noma (Fig. 3E).
In order to validate results obtained in vivo, mammary tissue has been mimicked in vitro by preparing spec-
imens containing cross-linked albumin (representative of epithelial tissue, showing in the QPs, Fig. 4A green 
points) and oil (representative of fat tissue, not showing quadrupolar peaks, Fig. 4A black points) at different ratios 
(i.e. BSA/oil is 0, 0.1, 0.33, 0.50, 0.66, 1). NMRD profiles have been acquired and analyzed to obtain insights into 
the slope of R1 vs. proton Larmor frequency (log/log curve) (Fig. 4B,C). In analogy to what happens for healthy 
Figure 3. Representative Hematoxylin/Eosin staining of breast tissue at different stages: (A) healthy Balb/c 
mouse, (B) NeuT mouse at 7w, (C) NeuT mouse at 15w, (D) NeuT mouse at 21w and (E) NeuT mouse at 30w 
(Magnification 20x).
Figure 4. (A) NMRD profiles of specimens containing cross-linked BSA and oil at different ratio; (B) Linear 
fitting of NMRD profiles (in the log/log scale); (C) Slope of the linear curves vs. BSA/oil ratio.
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mammary tissue, the specimen containing only oil displays an overall high and constant R1 value (Fig. 4A). QPs 
are not present and the curve slope is low (Fig. 4B,C). Upon increasing the amount of cross-linked BSA, there 
is an increase of the slope of the curve. This slope is proportional to the molar fraction of BSA in the analyzed 
specimen, with a behavior which strongly resembles the one reported for ex vivo excised tissues (Fig. 4C). QPs are 
present in all specimens containing BSA, also when only 10% of the specimen is composed by BSA. Therefore, the 
occurrence of cross-linked albumin is well detectable by the presence of peaks (on/off response).
The access to the cross-linked BSA/oil specimens has allowed an in-depth evaluation of the role of the 
Mz-(Magnetization) acquisition protocols on the appearance of QPs in the NMRD profiles. It has been found that, 
upon increasing the τ values and analyzing the Mz-recovery curve as a bi-exponential function, the intensities of 
QPs in the ex vivo mammary tumor containing tissues did not change much. The acquisition of the Mz-recovery 
curve in the latter specimens was carried out considering a mono-exponential behavior for calculation of the T1 
values as it is routinely done in FFC-relaxometry studies31.
Discussion
In the case of Breast Cancer, it is well established that a positive outcome is markedly dependent on the time it is 
diagnosed. Therefore, much attention is devoted to methods that allow detection at an early stage, even when no 
macroscopic sign of disease is present1,4.
Herein, a transgenic mouse model of breast cancer, BALB-NeuT, has been investigated22. This model recapit-
ulates human breast cancer development, including mammary simple hyperplasia, atypical hyperplasia, CIS and 
invasive breast cancer. Moreover, BALB-NeuT mice overexpress the activated form of the ErbB2 (Her/2-neu) 
oncogene, whose amplification is typically observed in 20–30% of human breast tumors32,33.
Herein reported in vivo results showed that breast cancer is detectable in T2w (T2-weighted) MR images only 
from 15w, when main portions of the gland are characterized by hyperplasia (simple or atypical).
The mammary glands visualized in vivo by MRI were analyzed ex vivo by recording the FFC-NMRD profiles. A 
characteristic feature of the NMRD profile of healthy mammary gland tissue is the high value of R1 over all the range 
of investigated B0 fields. This finding appears to be associated to the overwhelming presence of adipocytes with their 
typical large lipidic content. In these cells, water content is scarce and cytoplasmatic proteins occupy a limited space 
between the lipidic drops and the cellular wall. The constancy of R1 may be accounted in terms of the fact that the 
proton signal is essentially generated by a dominant lipidic component. Interestingly the hyperplasia step removes 
this constrain and the newly formed cells display a 1H relaxometric response that is driven by the water content and 
dynamics, as witnessed by the higher slope of the normalized R1 function vs. B0 and the appearance of the 14N-QPs.
The results from the ex vivo mammary tumor specimens have been validated in vitro by acquiring NMRD pro-
files of samples containing different ratios of cross-linked BSA mixed and oil. Interestingly, an analogue behavior 
as the one observed for mammary tissue, either in terms of shape and QPs appearance, is occurring in the in vitro 
experiments on the mixtures of BSA and oil.
Therefore, FFC-NMRD profiles appear to be well suitable for reporting about breast tumor onset and devel-
opment. In normal healthy mammary gland tissue, no 14N-QP is present. On the contrary, three peaks are clearly 
detected (0.7, 2.1 and 2.8 MHz) at each stage of cancer growth, already at the very early stage (5–7w). On this 
basis, the presence of 14N-QP can be considered a proper biomarker of tumor onset, with an on/off effect. This 
behavior is associated to the transition from normal mammary gland tissue, essentially composed by adipose 
tissue, to epithelial-like tissue in the presence of cancer. In epithelial-like tissue, immobilized proteins are present, 
that are responsible for the occurrence of the 1H-14N cross relaxation mechanism at the basis of the generation of 
quadrupolar peaks in the longitudinal water proton relaxation rates (R1).
The observation that no significant quantitative difference in the QPs’ parameters is present at different stages 
of tumor development appears to be independent on the acquisition protocol of NMRD profiles.
In fact, by using the same time intervals (τ values) in the acquisition of Mz-recovery curve, it happened that 
the contribution from different T1 value is not well matched with the relative concentration of those proton 
sources. Support to this explanation has been gained in the in vitro experiments on cross-linked BSA/oil spec-
imens by extending the number of τ values and analyzing the Mz-recovery curve as a bi-exponential function. 
It has been found that the intensity of the QPs is, as expected, to some extent modulated by differences in the 
protocol used for the acquisition of the NMRD.
By analyzing the overall shape of the NMRD profiles, more insights into the tissue characteristics can be gained. 
The linear fitting of log/log NMRD profiles has been shown to be particularly useful for establishing differences 
among the different tumor stages as each stage appears characterized by a peculiar slope of the linearized NMRD 
profile. In particular, the slope appears very small for healthy tissue and increases with the progression of the disease.
It follows that, on one hand the occurrence of 14N-QPs provides evidence for the presence of tumor cells and, 
on the other hand, the overall NMRD shape provide information on the tumor development stage.
One limitation of this study is related to the fact that it has been only carried out on ex vivo breast specimens, 
because the currently available FCC-NMRD instruments do not allow the in vivo acquisition of NMRD profiles 
of mammary tumors. Nevertheless, the overall T1 of tissues, analyzed at different tumor stages, showed to add rel-
evant information in the characterization of mammary gland tumor, making possible the early detection (5–7w) 
and further characterizations of tumor phenotypes.
On this basis, it appears evident that FCC-NMRD may have a very high potential in cancer diagnosis and in 
the establishment of tumor signatures.
Next steps will have to deal with the development of variable magnetic field MRI scanners, able to provide 
3D images of tissues at variable and low (<0.24 T) magnetic fields. One may expect that, by using this approach, 
it will be possible to perform the acquisition of two images (e.g. one at B0 = 0.24 T and another one tenth of this 
value) whose ratio will parallel the slope herein detected from NMRD profiles, thus reporting about the presence 
of the tumor and, eventually, the development stage.
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Conclusions
The herein reported results show that FFC-NMRD profiles provide useful insights for the early detection and 
characterization of breast cancer. Two complementary information can be gained from the analysis of the profiles. 
The onset of 14N-QPs is highly specific of the presence of tumor, thus providing an unambiguous on/off informa-
tion. In fact, QPs peaks are specifically present only when tumor cells are present in the breast tissue and, more 
importantly, they show up already at a very early stage of tumor development.
Another relevant information is gained by looking at the overall profile’s shape. The overall slope of the NMRD 
profile reports about the tumor stage, making it possible to distinguish different tumor phenotypes.
In summary, one may conclude that FFC relaxometry of tumor containing tissue can be a tool for the very 
early diagnosis and characterization of breast cancer. This observation provides a strong support to the role that 
FFC-MRI scanners may have in the diagnostic arena and prompts the development of FFC-NMR instruments for 
in vivo acquisition of the T1 dependence from the applied magnetic field imaging and diagnosis18,20.
The herein reported results show that new avenues to breast cancer diagnosis without the use of exogenous 
contrast agents are possible eventually using MRI scanners working at magnetic fields lower than the ones cur-
rently available in clinic (i.e. B0 < 0.2 T).
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